Lung Cancer – NCI-05-C-0010
Dr. David Schrump
Principal Investigator
NCI is currently conducting the following trial for patients with advanced primary lung or esophageal cancer, malignant pleural mesothelioma, or pleural metastases. Click on the trial below for additional details, including a summary of eligibility criteria, treatment plan, and information on how to contact Dr. Schrump and his staff directly.
You may also call the Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937) to inquire about referring a patient to this trial.
- Patients are hospitalized for approximately 6 days every third week (1 week of treatment, 2 weeks home) and this is repeated four times over 12 weeks
- Patients receive a 4-hour depsipeptide infusion followed by a 72-hour flavopiridol infusion each week of treatment
- Participants undergo a total of two tumor biopsies, one before treatment and one after treatment
- Participants will be required to get outpatient lab work two times a week
Why is this trial important?
This trial is being done because previous animal and laboratory studies show that these medicines have reduced the growth of different types of tumor cells, and the initial studies in humans found that these medicines can be given safely. This trial is to test the safety of two experimental medications given together as well as testing the effects of this drug combination on the patients' cancer. Based on our laboratory studies, we think if we give these two drugs together, they will work better at shrinking cancers than either one given alone.
Back to Top
